Salarius Pharmaceuticals

Salarius Pharmaceuticals will be renamed Decoy Therapeutics effective January 8, 2026, and will trade under the ticker DCOY; the stock rose 11.7% in premarket trading. The rebranding reflects a strategic shift toward peptide‑conjugate therapeutics, initially focusing on viral and oncological targets. Decoy Therapeutics plans to advance an AI‑powered platform to accelerate drug candidate selection; its lead antiviral program has attracted interest from BARDA and global health organizations. The name change does not affect the number of outstanding shares, shareholder rights, or operational leadership. » More on de.investing.com

Salarius Pharmaceuticals has postponed its annual meeting originally scheduled for December 19, 2025 to December 31, 2025 at 10:00 a.m. Central Time because only about 30% of the shares were represented, short of the required 34% quorum. The meeting will remain virtual via webcast, and the original record date of October 24, 2025 for eligible shareholders remains in effect. Shareholders who have not yet voted are urged to cast their votes online, by phone, or through proxy advisor Alliance Advisors. » More on de.investing.com

Salarius Pharmaceuticals announces that, following its combination with Decoy Therapeutics in early January 2026, it will rename itself Decoy Therapeutics and change its ticker symbol to DCOY. The merged company will focus on a peptide‑conjugate platform for antiviral and oncology therapies; leading antiviral programs are drawing attention from BARDA and global health organizations. Salarius reported a net loss of $5 million over the past twelve months, plans a $7 million offering at $1.50 per share and aims to strengthen its capital structure; the current ratio is 3.28. The stock is currently regarded in analysis as undervalued and oversold; the rebranding does not require shareholder approval. » More on de.investing.com